Medicine and Dentistry
Assay
37%
Atherogenesis
12%
Atherosclerosis
12%
Bosutinib
25%
Cardiovascular System
12%
Cell Adhesion Molecule
37%
Cell Function
100%
Cell Metabolism
12%
Cell Migration
25%
Cell Survival
100%
Cells
25%
Chemotherapeutic Agent
12%
Chronic Myelogenous Leukemia
25%
Dasatinib
62%
Drug
12%
Drug Megadose
25%
Endothelial Cell
100%
Endothelial Leukocyte Adhesion Molecule 1
25%
Endothelium
12%
Enzyme Linked Immunosorbent Assay
25%
Imatinib
12%
In Vitro
100%
Inpatient
12%
Intercellular Adhesion Molecule 1
25%
Lactate Dehydrogenase
25%
Lipoprotein
12%
Monitoring
12%
Necrosis
12%
Nilotinib
50%
Patient
12%
Ponatinib
62%
Therapeutic Procedure
25%
Tyrosine-Kinase Inhibitor
100%
Vascular Cell Adhesion Molecule 1
25%
Wound Closure
12%
Biochemistry, Genetics and Molecular Biology
Adhesion
37%
Bosutinib
25%
Cell Function
100%
Cell Metabolism
12%
Cell Migration
25%
Cell Survival
100%
Dasatinib
62%
Development
12%
Drug Megadose
25%
E-Selectin
25%
ICAM-1
25%
Imatinib
12%
Lipoprotein
12%
Molecule
37%
Myeloid
25%
Nilotinib
50%
Permeability
12%
Ponatinib
62%
Tumor Necrosis Factor
12%
Tyrosine Kinase Inhibitor
100%
VCAM-1
25%
Wound Healing Assay
25%
Pharmacology, Toxicology and Pharmaceutical Science
Atherogenesis
12%
Atherosclerosis
12%
Bosutinib
25%
Cell Adhesion Molecule
37%
Chronic Myeloid Leukemia
25%
Dasatinib
62%
Drug
12%
E-Selectin
25%
Enzyme-Linked Immunosorbent Assay
25%
Imatinib
12%
Intercellular Adhesion Molecule 1
25%
Lactate Dehydrogenase
25%
Lipoprotein
12%
Necrosis
12%
Nilotinib
50%
Ponatinib
62%
Protein Tyrosine Kinase Inhibitor
100%
Survival
100%
Vascular Cell Adhesion Molecule 1
25%
Wound
12%